Subscribe
Share
Share
Embed
Board Pearls is a gastroenterology board review built around clinical reasoning, not recall. Each episode takes one high-yield topic and works it the way you would on rounds: a case to anchor it, the framework that sorts the differential, and the specific decisions the exam rewards.
The gastroenterology series covers the full blueprint across nine modules: esophagus, stomach and duodenum, small bowel, colon, pelvic floor, liver, pancreas and biliary, endoscopy, and the cross-cutting topics. Episodes are grouped by chapter and built from the primary guidelines and pivotal trials the boards draw from (ACG, AGA, AASLD, ASGE), not from textbook summaries.
Use it as an audio companion to the written curriculum, MCQs, and AI tutor at boardpearls.com. Questions or feedback: hello@boardpearls.com.
Welcome to Board Pearls. This is episode one of two of the GERD and Refractory Reflux chapter, in the Esophageal Disorders module. In this episode we cover the mechanisms, the endoscopic grading, and the acid suppression ladder: GERD is a barrier failure problem before it is an acid problem, LA grading stratifies treatment intensity and Barrett risk, and the timing of acid suppression decides whether the regimen works.
The most useful move at the start of a GERD vignette is to ask what is wrong with the barrier rather than how much acid the patient is making. Acid output in GERD is usually normal. What fails is the apparatus that keeps acid in the stomach. Once that frame is in place, the rest of the chapter falls into a sequence. The barrier is the lower esophageal sphincter and the crural diaphragm acting in series. The angle of His and the intra-abdominal segment of esophagus support them. Reflux happens when one of those elements fails, or when a transient event opens the gate at the wrong moment.
Manometry at the esophagogastric junction reads a combined signal. The intrinsic LES is a two to four centimeter zone of tonically contracted smooth muscle in the wall of the distal esophagus and proximal stomach. It runs ten to thirty-five millimeters of mercury above the gastric body. The crural diaphragm is striated muscle that wraps the esophagus at the hiatus. It contracts with every breath and with every cough or strain. That contraction pinches the esophagus closed precisely when the abdominothoracic pressure gradient most favors reflux. The two structures sit on top of each other anatomically. The manometry probe records the sum. That is why an LES pressure reading on a manometry report is really an esophagogastric junction pressure.
The first surprise in GERD physiology is that most patients have a normal resting LES pressure. A hypotensive LES under ten millimeters of mercury shows up in severe reflux esophagitis, but it is the exception. The dominant mechanism of reflux is not a slack sphincter sitting open. It is the transient lower esophageal sphincter relaxation. A TLESR is a sudden collapse of LES pressure that is not preceded by a swallow, lasts longer than ten seconds, and is not accompanied by a peristaltic wave. It is a vagally mediated component of the belch reflex, triggered by gaseous distention of the gastric fundus. The nucleus tractus solitarius integrates the gastric afferent signal and orchestrates sphincter relaxation, crural inhibition, and shortening of the esophagus to vent gas. Cholecystokinin-1 receptors in the LES muscle mediate the intrinsic relaxation. GABA-B receptors on inhibitory neurons brake the reflex. That last detail is the reason baclofen, a GABA-B agonist, reduces TLESR frequency and reduces reflux events.
Healthy people have two to six TLESRs per hour. The frequency itself is not what is increased in GERD. What is increased is the proportion of TLESRs that carry acid into the esophagus rather than gas. A normal physiologic event becomes pathologic when there is an acid pocket sitting in the fundus ready to be vented along with the gas. Hold that frame, because the acid pocket is going to come back when we get to alginate therapy.
The sliding hiatal hernia is the structural amplifier that converts a marginal barrier into clinical disease. When the gastroesophageal junction migrates into the chest, the intrinsic LES is pulled away from the crural diaphragm. The two components of the barrier are no longer stacked. The intrinsic sphincter alone cannot withstand the abdominothoracic gradient during inspiration or strain. Crural contraction in this configuration does not help the sphincter. It creates an intrathoracic pouch of stomach whose contents are immediately available for reflux. The flap valve effect of the angle of His is lost. TLESR frequency rises because gastric distention is more easily transmitted to the receptors that trigger the reflex. And esophageal clearance is impaired, because material emptied into the hernia sac re-refluxes during the normal swallow-associated relaxations that follow.
Hiatal hernia size matters because the size cutoffs drive the choice of antireflux procedure. A hernia under two centimeters is compatible with transoral incisionless fundoplication. A hernia under three centimeters is compatible with magnetic sphincter augmentation in selected patients. A hernia over three centimeters changes the operation. It mandates a formal crural repair and pushes the patient toward a laparoscopic partial or full fundoplication. The number to measure at endoscopy is the distance from the diaphragmatic pinch to the proximal extent of the gastric folds. That number belongs in the report.
The American Foregut Society endoscopic classification grades the flap valve in retroflexion. Grade one is the intact barrier. No hernia. A snug aperture against the scope. An omega-shaped flap valve. Grade two is no hernia but a widened aperture up to two centimeters with a flattened flap valve. Grade three is a small hernia up to two centimeters with an aperture up to three centimeters and no flap valve. Grade four is a large hernia, a wide-open aperture, and no flap valve at all. The AFS grade is the modern endoscopic substrate for selecting a surgical or endoscopic antireflux procedure.
The acid pocket is the postprandial layer of unbuffered acid that sits on top of the food bolus in the gastric cardia, just below the squamocolumnar junction. After a meal, the ingested food buffers the bulk of the stomach contents. The fresh acid secreted afterward floats on top, because it is less dense and has not had time to mix. When a TLESR fires in that setting, the acid pocket is preferentially refluxed, because it is the layer closest to the LES. A sliding hiatal hernia makes this worse, because it pulls the cardia and the acid pocket closer to the esophagus and sometimes above the diaphragm. The mechanism explains why postprandial reflux outpaces what acid output predicts. It also explains how alginate works. Alginate forms a gel raft on contact with gastric acid that floats on top of the gastric contents. The raft displaces the acid pocket distally, out of reach of the next TLESR. That is why alginate is useful for postprandial breakthrough symptoms even in a patient who is otherwise on a PPI.
Esophageal clearance is the second line of defense once reflux has happened. Refluxed acid is cleared by gravity and primary peristalsis in seconds. The small residual is neutralized by swallowed alkaline saliva. A smaller contribution comes from bicarbonate in the submucosal esophageal glands. Two scenarios make clearance the limiting factor and they are both favored boards material. Recumbency abolishes gravity and reduces swallowing and salivation at the same time. That is why nocturnal reflux is disproportionately damaging, and why head of bed elevation actually changes acid exposure rather than just sounding like advice. The second scenario is salivary failure. Sjogren syndrome and head and neck radiation reduce saliva. The patient may have a normal acid burden by ambulatory testing and still have refractory symptoms, because the neutralization step is gone. Ineffective esophageal motility, the failed or weak swallow pattern under the Chicago Classification, prolongs acid contact time the same way and is overrepresented in erosive disease.
Obesity drives reflux through several converging mechanisms and they all tie pathogenesis to management. Visceral adiposity raises intra-abdominal pressure. That biases reflux upward at every TLESR. Obese patients have a higher prevalence of hiatal hernia and more TLESRs induced by gastric distention. Visceral fat secretes cytokines that impair esophageal barrier integrity by dilating intercellular spaces. Central obesity is the strongest modifiable risk factor for Barrett esophagus and esophageal adenocarcinoma. That is why weight loss is on the GERD treatment list. It is also why Roux-en-Y gastric bypass is the antireflux bariatric operation of choice, and why sleeve gastrectomy worsens reflux and is the wrong choice in an obese patient who already has GERD.
The last piece of the barrier story is the brain-gut axis. When the barrier is functioning normally, the small number of physiologic reflux episodes that occur are not perceived, because afferent signaling and central pain processing are calibrated to ignore them. In reflux hypersensitivity, the gain on that pathway is set too high. Physiologic reflux events generate symptoms even though acid exposure time is normal. That mechanism overlaps with functional heartburn. The Lyon Consensus framework sorts these patients out using pH-impedance, and we will pick that up in episode two.
That covers the barrier. Now turn to the endoscopy, because the endoscopic pattern in a GERD vignette decides treatment intensity, surveillance obligations, and surgical candidacy in a single image. The Los Angeles classification grades erosive esophagitis on mucosal break length and circumferential extent.
Grade A is one or more mucosal breaks no longer than five millimeters that do not bridge the tops of two adjacent mucosal folds. LA A is the lowest grade and it overlaps in appearance with what can be seen in normal subjects. That is why the Lyon Consensus 2.0 treats LA A combined with a borderline acid exposure time as supportive rather than definitive evidence of GERD.
Grade B is one or more breaks longer than five millimeters that still do not bridge fold tops. LA B is considered objective evidence of GERD under the Lyon 2.0 framework, although the older ACG framework was more cautious about it. Reflux monitoring off PPI is generally not required to confirm the diagnosis once LA B has been documented, although on-PPI testing may still be useful for refractory symptoms.
Grade C is contiguous mucosal breaks that bridge the tops of two or more folds and involve less than seventy-five percent of the circumference. LA C is severe disease. It is unambiguous objective evidence of GERD. It carries an elevated risk of Barrett esophagus on the post-healing endoscopy. Surveillance for Barrett begins after PPI healing, because acute inflammation can mask underlying intestinal metaplasia.
Grade D is contiguous breaks involving more than seventy-five percent of the circumference. LA D is the highest grade and the strongest predictor of Barrett at follow-up endoscopy. It is also the population in which vonoprazan outperforms a standard PPI most clearly, and we will get to that in a moment.
The shorthand recognition pattern for the boards is small break versus large break, then island versus continent. Under five millimeters and not crossing fold tops is A. Over five millimeters and still not crossing fold tops is B. Crossing fold tops and under seventy-five percent of the circumference is C. Over seventy-five percent of the circumference is D. C and D demand a follow-up endoscopy after PPI healing to look for Barrett. C and D obviate reflux monitoring, because the diagnosis is already objective.
Non-erosive reflux disease is the majority of GERD encountered clinically. The patient has typical heartburn or regurgitation, and the endoscopy is normal. The endoscopic gold standard is absent, so confirmation requires reflux monitoring, and the standard strategy in NERD is to test off PPI to establish the diagnosis. NERD does not warrant Barrett surveillance independent of standard age and risk-factor screening criteria.
Peptic stricture is the cicatricial complication that follows years of unhealed erosive disease. The patient presents with progressive solid food dysphagia, often with food impaction, on a background of long-standing heartburn that may have improved in recent months. That last detail is the clue. The stricture itself reduces the volume of refluxate, so the heartburn quiets down at the moment the lumen narrows enough to cause dysphagia. Diagnosis is at endoscopy with biopsies to exclude malignancy and eosinophilic esophagitis. Treatment is endoscopic dilation combined with high-dose PPI for healing of the underlying disease. The rule of threes governs balloon or bougie dilation. No more than three sequential dilator sizes once moderate resistance is encountered. Aggressive PPI therapy reduces the long-term repeat dilation rate to roughly thirty percent.
Schatzki ring sits next to peptic stricture on the differential and the boards reward candidates who recognize the difference. A Schatzki ring is a thin, diaphragm-like, circumferential mucosal fold at the squamocolumnar junction with squamous epithelium above and columnar below. The patient describes intermittent solid food dysphagia, with episodes weeks to months apart. The classic story is the steakhouse impaction that resolves spontaneously or after a liquid washdown, with normal swallowing in between. Treatment is single-pass dilation with a large caliber bougie or balloon, around forty-five to sixty French, intended to fracture the ring rather than progressively stretch it. The role of GERD in Schatzki ring pathogenesis is disputed, but PPI after dilation reduces recurrence even in patients without overt reflux symptoms.
Long-segment Barrett esophagus rounds out the endoscopic recognition set. Salmon-colored mucosa extending above the gastric folds with biopsy-confirmed intestinal metaplasia is itself definitive objective evidence of GERD and obviates the need for reflux monitoring. The Prague C and M criteria quantify the extent. The Seattle protocol governs the biopsy approach. Those details belong to the Barrett chapter. The point for this chapter is that LA C and LA D demand a follow-up endoscopy after PPI healing specifically to look for Barrett that was previously masked by inflammation.
Now turn to the acid suppression ladder, because once the barrier has failed and the endoscopy has graded the disease, the question becomes how to suppress acid effectively. The mechanism of every step on the ladder is parietal cell centric. Understanding which channel each agent blocks explains the relative potency and the timing instructions that determine whether the drug will actually work.
The parietal cell secretes acid through the H plus K plus ATPase proton pump on its canalicular membrane. The cell is stimulated through three receptors. Gastrin binds the CCK-2 receptor. Histamine binds the H2 receptor. Acetylcholine binds the M3 receptor. All three pathways converge on the same final common pump. Blocking the pump is more effective than blocking any single upstream receptor, which is why PPIs heal erosive disease and H2 blockers do not.
The H2 blockers, famotidine and cimetidine and nizatidine, relieve mild GERD symptoms in roughly half to two thirds of patients. They heal erosive esophagitis poorly. The reason is tachyphylaxis. Within days, the parietal cell upregulates the other receptor pathways and the histamine block loses its effect. H2 blockers are useful for intermittent mild symptoms and as a short-term bedtime add-on in patients with documented nocturnal acid breakthrough on twice-daily PPI, although tachyphylaxis blunts the durability of even that strategy. Famotidine has the lowest excretion in breast milk and is the preferred H2 blocker during lactation. Ranitidine has been withdrawn for nitrosamine contamination and should not appear on a current vignette as the right answer.
Proton pump inhibitors bind covalently to the activated proton pump on the canalicular membrane. The covalent binding is irreversible. But the parietal cell continuously synthesizes new pumps, and the PPI plasma half-life is only about ninety minutes. Two consequences follow that the boards exploit relentlessly.
The first is that a PPI is a prodrug. It requires acid activation in the parietal cell canaliculus, and acid activation only happens during active acid secretion, and active acid secretion only happens at meals. PPIs must be taken thirty to sixty minutes before breakfast. When twice-daily dosing is needed, the second dose goes thirty to sixty minutes before dinner. A PPI taken at bedtime or with food misses most of its target population of activated pumps. This is the single most common reason a patient has been mislabeled as PPI-refractory. The Spechler trial in 2019 referred three hundred sixty-six patients for PPI-refractory heartburn, and twelve percent responded to a structured PPI trial with explicit meal-timing instructions. Those patients did not have refractory disease. They had incorrect timing. The first move in any PPI failure vignette is to confirm the patient is taking the drug before a meal rather than at bedtime or with food. Dexlansoprazole is the partial exception. Its modified release formulation has two release phases in the proximal and distal small bowel and does not require strict meal timing.
The second consequence is that PPIs require three to five days to reach steady state. The parietal cell keeps making new pumps that have to be inactivated, and the inhibition accumulates. That is why PPIs are useless for acute on-demand symptom control. Antacids and alginate handle the acute symptom. PPIs do the suppression.
PPIs are metabolized primarily by CYP2C19. The enzyme is polymorphic and the distribution produces wide interindividual variation in metabolism. Rapid metabolizers clear the drug faster and may need higher or twice-daily dosing for the same effect. Rabeprazole and esomeprazole are less affected by the polymorphism, which makes them attractive when a rapid metabolizer phenotype is suspected.
The PPI relative potency ladder is worth holding loosely, and here it is from weakest to strongest. Pantoprazole twenty milligrams sits at the bottom at about a quarter of an omeprazole equivalent. Omeprazole twenty milligrams is the reference. Lansoprazole fifteen milligrams is close to one omeprazole equivalent. Esomeprazole twenty milligrams is about one and a half. Rabeprazole twenty milligrams is the most potent of the standard PPIs by pH4-time analysis. The ladder matters when escalating a refractory patient. Switching from pantoprazole to rabeprazole or esomeprazole moves the patient up the potency curve before adding a second daily dose.
Standard PPI dosing for GERD follows a step-up framework. Once-daily PPI before breakfast at FDA-approved dose heals eighty to ninety-five percent of erosive esophagitis and controls symptoms in most patients with NERD over eight to twelve weeks. Twice-daily dosing is reserved for inadequate symptom response, severe LA C or D disease at presentation, peptic stricture, and Barrett esophagus management. Maintenance therapy after healing is required in most patients with severe erosive disease, because reflux recurs within weeks of stopping the drug. The maintenance dose generally equals the healing dose. De-escalation to the lowest effective dose, or to on-demand dosing, or even to a drug holiday is appropriate in NERD and in mild erosive disease once symptoms are controlled.
Seventy to eighty percent of patients on twice-daily PPI experience nocturnal gastric acid breakthrough. Gastric pH falls below four for more than an hour at night despite adequate daytime suppression. The classic vignette is a Barrett patient on twice-daily omeprazole with adequate daytime control who wakes at three in the morning with burning chest pain. A bedtime H2 blocker can be added as a short-term measure, with the caveat that tachyphylaxis limits how long the strategy keeps working.
Vonoprazan is the next rung on the ladder and it represents a meaningfully different class. Vonoprazan is a potassium-competitive acid blocker, the only PCAB approved in the United States. The mechanism is ionic, not covalent. The drug binds both active and inactive proton pumps. That removes most of the constraints that limit a PPI. Vonoprazan is acid-stable and does not need an enteric coat. It is an active drug rather than a prodrug. It binds active and inactive pumps equally, so it does not need to be timed around a meal. The plasma half-life is seven to nine hours, far longer than the ninety-minute PPI half-life. Metabolism is primarily through CYP3A4 rather than CYP2C19, which removes the polymorphism issue.
By pH4-time analysis, vonoprazan ten milligrams approximates omeprazole sixty milligrams once daily, and vonoprazan twenty milligrams approximates omeprazole sixty milligrams twice daily. That makes vonoprazan considerably more potent than any FDA-approved PPI dose. The PHALCON-EE trial randomized just over a thousand patients with erosive esophagitis to vonoprazan twenty milligrams or lansoprazole thirty milligrams for eight weeks of healing, then to maintenance dosing. Vonoprazan was noninferior and superior to lansoprazole for both healing and maintenance overall. The largest absolute benefit was in LA grade C and D disease, where week-two healing was seventy point two percent for vonoprazan versus fifty-two point six percent for lansoprazole. That is an absolute difference of seventeen point six percentage points. The clinically useful summary is that vonoprazan is the answer for genuine breakthrough acid in a patient who has failed twice-daily PPI, and it is particularly compelling in severe erosive disease. Vonoprazan is also a component of newer H. pylori eradication regimens, where the higher and more consistent suppression improves antibiotic efficacy. The lactation caveat is that data on breast-milk exposure are absent and the drug should be avoided during breastfeeding.
PPI long-term safety has been the subject of intense observational research, and the candidate should be calibrated to the strength of the evidence. The list of observational associations is long. Vitamin B12 deficiency, hypomagnesemia, iron deficiency, calcium absorption changes, C. difficile infection, community-acquired pneumonia, interstitial nephritis, chronic kidney disease, microscopic colitis, food allergy, eosinophilic esophagitis, dementia, cardiovascular events, all-cause mortality. The mechanisms proposed are plausible. The reduced acid release of food-bound B12 is real. The dietary hypomagnesemia signal is real. But most of the rest came from observational data with potential for residual confounding, because patients who end up on long-term PPI therapy are sicker on average than those who do not.
The randomized data have largely reassured. The 2019 COMPASS substudy randomized about seventeen thousand six hundred patients on rivaroxaban or aspirin to pantoprazole forty milligrams daily or placebo for three years. There was no significant difference between PPI and placebo for any of the headline outcomes except enteric infections, which ran one point four percent versus one percent, an odds ratio of one point three three. The dementia and CKD signals in particular did not hold up. The boards now reward a measured response. PPIs are not a benign substance and should be used at the lowest effective dose for the shortest duration that controls disease. But a blanket discontinuation policy is not warranted. The wrong move in a vignette is to stop a PPI in a patient with severe erosive disease, peptic stricture, or Barrett esophagus on the basis of a long-term-safety question. The right move is to confirm that the indication still applies and that the dose is the lowest one that maintains control.
The clopidogrel pairing deserves a separate note because the pharmacokinetic concern still surfaces on examinations. Clopidogrel is a prodrug activated by CYP2C19. The same enzyme metabolizes PPIs. Omeprazole and esomeprazole in particular can reduce clopidogrel activation in laboratory studies. The clinical trials, including COGENT, have not shown a meaningful increase in cardiovascular events when PPIs are added to clopidogrel. Current guidance does not require avoiding PPIs in patients on clopidogrel. When concern arises, pantoprazole or rabeprazole are preferred because they have less CYP2C19 interaction. The recognition pattern in a vignette is a dual antiplatelet patient who needs PPI for ulcer prophylaxis. The right answer is to pick pantoprazole or rabeprazole rather than to withhold acid suppression.
One last housekeeping point. H. pylori testing is not indicated for GERD as such. GERD is neither an indication to test for H. pylori nor a contraindication to eradicate it. Eradication in patients with duodenal ulcer can occasionally unmask reflux esophagitis, and some data suggest H. pylori-induced fundic gastritis with reduced acid output may protect against Barrett and adenocarcinoma. The boards point is just that a GERD vignette is not the place to add an H. pylori workup.
So the way of thinking the episode teaches is sequential. The barrier is the LES and the crural diaphragm acting in series, supported by the angle of His and an intra-abdominal segment of esophagus. Most patients have a normal resting LES, and the dominant mechanism is the TLESR. The sliding hiatal hernia amplifies the problem by dissociating the LES from the crus, increasing TLESR frequency, abolishing the flap valve, and impairing clearance. The acid pocket explains postprandial breakthrough and tells you why alginate works. Salivary failure and recumbency convert a normal acid burden into refractory symptoms.
Then the endoscopy. The endoscopic grade reads as small break versus large break, then island versus continent. LA A and B are smaller breaks that stay within a fold span. C and D bridge fold tops. D takes more than three quarters of the circumference. LA C and D buy a post-healing endoscopy to look for Barrett, and they are the population where vonoprazan opens the biggest gap over a standard PPI.
Then the drugs. The acid suppression ladder is mechanism-first. H2 blockers fail in erosive disease because of tachyphylaxis. PPIs are prodrugs that bind active pumps, so they must be taken before meals and accumulate over three to five days. Pantoprazole is the weakest of the standard PPIs and rabeprazole the strongest. Vonoprazan ionically binds active and inactive pumps, has a seven to nine hour half-life, runs on CYP3A4, ignores meal timing, and is the answer for genuine PPI failure especially in LA C and D disease.
And the safety calibration. The long-term safety signals from observational studies have not held up in randomized data, with only a modest signal for enteric infections. The right response is the lowest effective dose for the shortest duration rather than reflexive discontinuation.
In episode two we move to the patient whose PPI has failed. The Lyon Consensus framework splits proven reflux from reflux hypersensitivity and functional heartburn. Antireflux surgery selection follows only after objective reflux is documented. And the workup of the PPI-refractory patient is mostly the workup of a diagnosis that turns out not to be GERD at all.